# The Articular Chromatin Landscape in Osteoarthritis

## TL;DR

This review explores how changes in chromatin structure and epigenetics contribute to osteoarthritis and how these insights can guide new drug development.

## Contribution

The paper highlights the role of chromatin dynamics and epigenetic disruptions in OA pathogenesis and their potential for targeted drug discovery.

## Key findings

- OA is a polygenic disease where genetic factors disrupt chromatin landscapes, leading to abnormal gene expression.
- Epigenetic editing technologies offer new opportunities for targeted regulation of OA-relevant genes.
- Most OA-associated SNVs are in non-coding regions and affect gene expression rather than protein sequence.

## Abstract

What are the main findings?
Emerging data from multidimensional and high-resolution phenotyping of disease-relevant tissues indicates that osteoarthritis (OA) is a polygenic disease, where genetic factors disrupt the chromatin landscape in disease-relevant cells leading to aberrant expression of effector genes that drive OA pathogenesis.According to the concept of a developmental origin for OA, the functional cooperation between chromatin dynamics and transcription factors (TFs) regulates the unfolding of a development-specific gene expression program, defines the outcome of skeletogenesis, and ultimately determines the articular biomechanics and the risk of OA.

Emerging data from multidimensional and high-resolution phenotyping of disease-relevant tissues indicates that osteoarthritis (OA) is a polygenic disease, where genetic factors disrupt the chromatin landscape in disease-relevant cells leading to aberrant expression of effector genes that drive OA pathogenesis.

According to the concept of a developmental origin for OA, the functional cooperation between chromatin dynamics and transcription factors (TFs) regulates the unfolding of a development-specific gene expression program, defines the outcome of skeletogenesis, and ultimately determines the articular biomechanics and the risk of OA.

What is the implication of the main findings?
Detailed mapping and functional characterization of the OA-associated chromatin conformation and epigenetic disruptions may accelerate the discovery of disease-modifying drugs for OA.Novel technologies pave the way for precise epigenetic editing at the desired genomic regions and may allow a targeted transcriptional regulation of OA-relevant genes in disease-relevant cells.

Detailed mapping and functional characterization of the OA-associated chromatin conformation and epigenetic disruptions may accelerate the discovery of disease-modifying drugs for OA.

Novel technologies pave the way for precise epigenetic editing at the desired genomic regions and may allow a targeted transcriptional regulation of OA-relevant genes in disease-relevant cells.

Recent technological breakthroughs have enabled multidimensional phenotyping, with unprecedented single-cell resolution and genome-wide coverage, across multiple osteoarthritis (OA)-relevant tissues, such as articular cartilage, synovium, infrapatellar fat pad, and subchondral bone. The majority of the single nucleotide variations (SNVs) that have been associated with OA are located in non-protein coding regions and confer risk for disease by altering the expression level, instead of the amino acid sequence of the gene product. These data have shaped the concept of OA as a polygenic disease, where genetic factors disrupt the chromatin landscape in disease-relevant cells, leading to aberrant expression of effector genes. Pharmacologic manipulation of the OA-driving epigenetic landscape has recently emerged as an attractive path for the development of disease-modifying drugs. Novel clustered regulatory interspaced short palindromic repeats (CRISPR)-based technologies provide opportunities for precise epigenetic editing at the desired genomic regions and may allow a targeted transcriptional regulation of disease-relevant genes in disease-relevant cells. The aim of the present narrative review is to summarize the emerging data on the role of epigenetic factors and chromatin structure as calibrators of the risk for developing OA and to discuss the opportunities and challenges arising from the use of chromatin landscape to guide drug discovery.